Colorectal cancer (CRC) is a heterogeneous disease and one of the most prevalent malignancies worldwide. Previous research has indicated that phosphatase and tensin homolog (PTEN)-related genes found in CRC may serve as potential biomarkers for individualized treatment options. The present study aimed to examine the association between PTEN-related genes and the prognosis of CRC patients by evaluating the significance of PTEN-related hub genes and determining potential mechanisms and genes associated with them. Gene expression profiles and clinical information were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. At present, PTEN mutations have been identified in 7% of CRC patients, according to the most recent TCGA data. Differential expression analysis revealed 54 genes as differentially expressed genes (DEGs) between PTEN-related genes and GEO databases (GSE39582 and GSE6263). Further gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were conducted on PTEN-related DEGs. The prognostic efficacy of the PTEN-related DEG signature was assessed using Kaplan–Meier survival and receiver operating characteristic curve analyses. Bioinformatics methods were utilized to analyze the correlation between PTEN-related DEGs and CRC prognosis, survival, and drug efficacy. Through these analyses, eight prognostic-related PTEN-related hub genes (PPARGC1A, NTRK2, ANK2, PLCB4, STC2, PLAU, CDKN1A, and HPGDS) were identified and a risk prognosis model was constructed. Notably, NTRK2 and HPGDS were found to affect drug treatment response in CRC. Targeting these prognostic-related PTEN-related hub genes can regulate cell death signaling, which may benefit the prognosis of CRC patients and improve drug sensitivity.

Background: Temperature control plays a pivotal role in patients with heat stroke (HS), but little work has been done sufficiently on the use of temperature control to reflect disease progression. Here, we defined and analyzed the concrete role of controlling time for core temperature to physiological level (CTTP), in order to explore a potential index to guide the treatment of HS.

Method: This is a retrospective cohort study. From three hospitals located in Sichuan province, China, we collected a total of 179 HS cases with clinical diagnosis and treatment records. We defined CTTP as the time interval of HS onset to stabilization of core temperature (rectal temperature) below 37.7°C and analyzed the correlation between CTTP and inpatient death of HS patients.

Results: Of all the cases, 64.80% were male and 53.07% were exertional heat stroke (EHS). The median (IQR) age was 59 (23.5–73) years old, and the median (IQR) onset temperature was 42 (40.4–42)°C. Multivariable analysis demonstrated significantly high inpatient death in the highest CTTP tertile (>18 h) (hazard ratio: 18.75; 99% confidence interval: 4.06–86.59; p = .0002). In addition, compared with patients in lowest CTTP tertile, patients in highest CTTP tertile were at significantly higher risk of organ damage: 3.48-fold for respiratory failure (95% CI: 1.41–8.59, p = .0069); 3.18-fold for shock (95% CI: 1.37–7.39, p = .0071); 4.09-fold for rhabdomyolysis (95% CI: 1.73–9.64, p = .0013); 4.64-fold for renal damage (95% CI: 2.12–10.14, p = .0001).

Conclusion: Long of CTTP predicts inpatient death of HS patients with a CTTP tertile >18 h associated with the highest rate of inpatient death.

This study aimed to investigate the risk factors for the onset of subsequent primary breast cancer (SPBC) in women with a previous diagnosis of early-stage breast cancer (BC) and to construct a prognostic prediction model for patients with SPBC. Using the Surveillance, Epidemiology, and End Results-17 (SEER-17) database, we conducted a retrospective cohort analysis on women with initial primary early-stage BC from 2004 to 2015. Standardized incidence ratio (SIR) was calculated to determine the risk of subsequent primary cancer (SPC). A competing risk model was built to identify the risk factors for the onset of SPBC. And risk factors associated with breast cancer-specific mortality in SPBC patients were evaluated and presented in the form of nomogram. Compared with the general population, the overall risk of SPC for all sites was significantly elevated in women with early-stage BC (SIR = 1.21, 95% CI: 1.20–1.23), and breast is the most frequent site. Age, race and ethnicity, year of diagnosis, history of other tumors, histological type, surgery, radiation, chemotherapy, tumor size, positive lymph nodes numbers and ER status were independent risk factors (p < .05) for the onset of SPBC. A new prognosis nomogram demonstrated good discrimination after internal validation with a C-index of 0.869 (95% CI: 0.859–0.880), and showed favorable consistency and clinical usefulness. The incidence of SPBC and prognosis of patients with SPBC were well estimated based on a large cohort. Our nomogram model had excellent prediction performance and could be a useful tool to predict prognosis.

To investigate the imaging manifestations and pathological features of ocular adnexal lymphoma (OALs) in order to provide relevant information for ophthalmologists. A total of 94 patients with OALs were pathologically confirmed between August 2018 and July 2023, and their demographics, location, subtype, treatment, and prognosis were retrospectively studied. 94 patients with OALs were included in this study, of whom 28 were female (29.79%) and 66 were male (70.21%). The age of the patients ranged from 21 to 80 years, with a predominance of 50–60 years (60/94); monocular onset was common (90/94), and the most site of onset was orbital (74/94), followed by conjunctiva (12/94), eyelids (4/94), vitreous (3/94), and lacrimal gland (1/94). CT and MRI can show the involvement and extent of the lesions, and the pathology of the disease is characterized by mucosa-associated lymphoid tissue marginal zone B-cell lymphoma (72/94), diffuse large B-cell lymphoma (10/94), T-cell lymphoma (4/94), mantle cell lymphoma (2/94), Burkitt's lymphoma (2/94), small lymphocytic lymphoma (2/94), and follicular lymphoma (1/94). All patients received surgical treatment, 42 patients received local radiation therapy, 35 patients received chemotherapy, 13 patients received radiation therapy and chemotherapy successively, and 3 patients received comprehensive treatment. During the follow-up, three patients relapsed, four died, one was lost to follow-up, and the remaining patients had stable conditions. The majority of OALs are mucosa-associated lymphoid tissue marginal zone B-cell lymphomas (MALT) with an excellent prognosis. It mostly occurs in people over 50 years of age and most site of the onset is orbital.

Circular RNAs (CircRNAs) are now under discussion as novel promising biomarkers for patients with various tumors. Our study aimed to identify circRNAs related to the progression of colon cancer and to further investigate their roles in the development of colon cancer base on The Cancer Genome Atlas database. The competing endogenous RNA (ceRNA) network was constructed based on 4 circRNAs, 14 miRNAs, and 229 mRNAs. Meanwhile, three hub genes were identified via the protein protein interaction networks (PPI) network. It should be noted that only RUNX1 targeted by circ-0084615 and mir-330-3p was confirmed as a survival-related gene. Further analyses indicated the possible function of RUNX1 in colon progression, such as angiogenesis, epithelial–mesenchymal transition, hedgehog signaling and so on. Further investigations were conducted into the correlation between RUNX1 expression profiles and immune cells. Finally, we validated the expression of the circ-0084615/mir-330-3p/RUNX1 axis in clinical specimens. In conclusion, we constructed ceRNA network and revealed that the circ-0084615/mir-330-3p/RUNX1 axis serves as a critical role in colon cancer.

This study aimed to assess the clinical efficacy and safety of aprepitant injection in preventing and treating nausea and vomiting induced by platinum-based chemotherapy in lung cancer patients. Forty-eight patients with advanced first-line lung cancer undergoing cisplatin- or carboplatin-based chemotherapy were randomly assigned to either the experimental group or the control group, with 24 patients in each group. The control group received dexamethasone and palonosetron for vomiting prevention, whereas the experimental group received dexamethasone, palonosetron, and aprepitant injection. The study compared the incidence of acute and delayed vomiting, functional life index (FLIE) scores for nausea and vomiting at 24 and 120 h postchemotherapy and the occurrence of adverse drug reactions between the two groups. The effective control rate of acute-phase vomiting in the treatment group was 83.33%, significantly higher than 45.83% in the control group, with a statistically significant difference (p < .05). The treatment group also demonstrated a higher effective control rate of delayed vomiting, with 75% compared with 41.67% in the control group, which was statistically significant (p < .05). Furthermore, FLIE scores in the treatment group at 24 and 120 h after chemotherapy were higher compared with the control group, with a statistically significant difference (p < .05). The incidence of complications such as fatigue, headache, dyspepsia, anorexia, hiccup, and constipation showed no significant difference between the two groups (p > .05). Aprepitant injection effectively prevents platinum-based chemotherapy-induced nausea and vomiting, enhances patients' quality of life, and demonstrates good safety, justifying its clinical adoption.